Participated · Series B · Aug 2026

Khartis Therapeutics is developing a pipeline of oral small molecule medicines, with a lead program that is an oral selective IGF-1R inhibitor designed for thyroid eye disease. The company is also advancing additional oral small-molecule programs against clinically validated immunology pathways. Khartis was founded in 2024 by Robert Hoffman (CEO and Head of Drug Discovery), Craig Murphy (CSO), and Chris LeMasters (Executive Chairman), and was incubated within Foresite Labs. It is headquartered in San Diego and its team includes many members who previously worked together at XinThera. Financially, Khartis has raised a total of $95 million following its $50 million Series B. The company intends to use the new financing to accelerate advancement of its lead program and continue discovery of differentiated small molecule medicines.

Led · Series C · Jun 2026

Flare Therapeutics is a clinical-stage biotech headquartered in Cambridge, Mass., that focuses exclusively on drugging transcription factors using an integrated discovery platform to identify ligands to previously undrugged proteins. The company has prioritized FX-111, a first-in-class degrader targeting ARON for prostate cancer, which received IND clearance and is expected to enter clinical development in Q3 2026. FlareTx is also advancing an ARON RIPTAC program through preclinical development to complement FX-111 and expand its ability to address AR-driven prostate cancer. Separately, FX-909, an oral PPARG inhibitor targeting luminal lineage biology in urothelial cancer, is in a Phase 1B dose expansion and the company intends to progress it via an external partnership. The recent $85M Series C provides capital to advance these programs, support working capital and general corporate purposes. The company appointed Anna Protopapas as CEO concurrent with the financing to guide its next phase of clinical and corporate development.

Led · Series A · Apr 2026

Stipple Bio leverages its Pointillist Platform to discover tumor-specific cell surface epitopes and develop precision oncology medicines designed to minimize on-target/off-tumor toxicity. Its lead candidate, STP-100, is a novel antibody-drug conjugate (ADC) incorporating tumor-specific binders and is expected to enter clinical studies in early 2027. The company plans to use its Series A proceeds to advance STP-100 into multiple early-stage clinical trials and to expand its pipeline by identifying additional high therapeutic-index targets. Stipple Bio was founded in 2022 by Dr. Aaron Ring and Dr. Aashish Manglik and is led by CEO Jeff Landau. The company recently added Derek DiRocco, PhD and Thilo Schroeder, PhD to its board and retains board members including Vineeta Agarwala and Greg Verdine. Stipple Bio raised $100M in its Series A round announced in April 2026.

Participated · Series B · Mar 2026

Atavistik Bio is advancing a lead program, ATV-1601, an oral AKT1-selective inhibitor being developed as a potential treatment for hereditary hemorrhagic telangiectasia (HHT), a rare genetic bleeding disorder with no approved therapies. The company is also developing a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms, a group of chronic blood cancers. The recent Series B extension increases available capital to support clinical development of ATV-1601 and further advancement of the JAK2 inhibitor. Atavistik previously announced a $120 million Series B in December 2025, and the extension brings total Series B proceeds to $160 million. Leadership has signaled the new funding will accelerate development toward improved efficacy and tolerability for patients, according to CEO Bryan Stuart.

Participated · Series F · Jan 2026

Parabilis Medicines is pioneering stabilized, cell-penetrant α-helical peptides, called Helicons™, to modulate intracellular proteins that small molecules and antibodies cannot reach. Its lead candidate, FOG-001 (zolucatetide), directly inhibits the β-catenin:TCF interaction within the Wnt/β-catenin pathway and has shown meaningful single-agent activity across five tumor types, including desmoid tumors and adamantinomatous craniopharyngioma. The drug has U.S. FDA Fast Track Designation for desmoid tumors and is moving toward a registrational trial while additional data in hepatocellular carcinoma and familial adenomatous polyposis are forthcoming. Beyond FOG-001, Parabilis is advancing preclinical Helicon degraders against ERG and allosteric ARON for prostate cancer, demonstrating the broad applicability of its platform. Headquartered in Cambridge, Massachusetts, the company leverages proprietary data, AI- and physics-based algorithms, and more than a decade of laboratory innovation. Financially, Parabilis closed an oversubscribed $305 million Series F round at an increased valuation, positioning it to expand clinical and preclinical programs. No revenue or user metrics have been disclosed, consistent with its clinical-stage status.